Trial · NCT07901790
Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis
NCT07901790, Not applicable, Recruiting, Yonsei University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis. Trials, record NCT07901790. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901790
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis
- NCT number
- NCT07901790
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 165 participants, estimated
- Lead sponsor
- Yonsei University
- Conditions
- Osteoarthritis, Knee, Knee Osteoarthritis
- Interventions
- Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs), Cross-linked Hyaluronic Acid (Synovian)
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 6 Months | Baseline and 6 months post-injection | The WOMAC total score assesses pain, stiffness, and physical function on a standardized scale. Higher scores indicate worse pain and functional limitation. The primary efficacy endpoint is the between-group difference in the change from baseline to 6 months post-injection, analyzed using analysis of covariance (ANCOVA). |
| Secondary | Change from Baseline in WOMAC Subscale Scores | Baseline, 1, 3, and 6 months post-injection | Changes in individual WOMAC subscales: pain (5 items), stiffness (2 items), and physical function (17 items). |
| Secondary | Change from Baseline in Visual Analog Scale (VAS) Pain Score | Baseline, 1, 3, and 6 months post-injection | Knee pain assessed on a 100-mm Visual Analog Scale (VAS, 0 = no pain, 100 = worst pain). |
| Secondary | Change from Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Subscores | Baseline, 1, 3, and 6 months post-injection | Changes in KOOS subscales (Pain, Symptoms, ADL, Sport/Rec, and QOL; each scored 0-100, where 100 represents no symptoms/best function). |
| Secondary | Proportion of Clinical Responders (MCID and OMERACT-OARSI criteria) | 6 months post-injection | Responder rates evaluated by minimal clinically important difference (MCID: WOMAC \>= 9-point reduction, VAS \>= 14-mm reduction) and OMERACT-OARSI criteria. |
| Secondary | Magnetic Resonance Imaging (MRI) Assessment of Cartilage | Baseline and 6 months post-injection | Evaluation of articular cartilage morphologic repair and progression using MOCART 2.0 (Magnetic Resonance Observation of Cartilage Repair Tissue) and MOAKS (MRI Osteoarthritis Knee Score). |
| Secondary | Radiographic Progression on Plain Radiographs (X-ray) | Baseline, 3 months, and 6 months post-injection | Changes in Kellgren-Lawrence (KL) grade and Hip-Knee-Ankle (HKA) mechanical alignment angle. |
| Secondary | Rescue Medication Usage | Throughout the 6-month study period | Proportion of participants requiring rescue medication (acetaminophen), cumulative tablet count, and days of rescue medication intake. |
| Secondary | Incidence and Severity of Adverse Events | Throughout the 6-month study period | Incidence, severity, and causality of all adverse events (AEs), serious adverse events (SAEs), and local injection-site reactions according to NCI-CTCAE v6.0 and WHO-UMC criteria. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901790
GET https://conductscience.org/api/trials/v1/NCT07901790/registered